Artificial intelligence technology has been employed to dramatically accelerate the development of a drug designed to treat obsessive-compulsive disorder (OCD).
Oxford-based Exscientia has collaborated with Japan’s Sumitomo Dainippon Pharma to produce a new drug for OCD. In the exploratory research phase, the application of Exscientia’s Centaur Chemist™ AI platform helped reduce the development time from what would normally take more than four years, to just 12 months.
Scientia’s chief executive, Professor Andrew Hopkins, explained the development represented a major breakthrough: “We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery.”
The Centaur Chemist™ platform works by converting drug discovery into a set of formalised steps and a system that learns from human experts. The rules of drug discovery are very complex and not easily described as a ready set of moves. Through repetition and the examples of human researchers, the algorithms become increasingly efficient. This enables breakthrough productivity gains, as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.
Oxford biotech company e-therapeutics is offering its powerful network-biology-and AI-based drug discovery platform to help tackle the Covid-19 pandemic.
Using its proprietary tech, a biotech company has discovered antibodies leading to the development of drug discovery programmes in kidney disease and cancer.
Researchers in Oxford and Zurich have used artificial intelligence (AI) and computer visualisation technology to detect changes in colon cancer cells that could be connected to the ‘expression’ of some smell-sensing genes.